-
Mashup Score: 2
What? Abstract #42: Ide-cel CAR-T therapy for relapsed/refractory multiple myeloma with renal impairment: real world experience Who? …
Source: nucleus.astct.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Early Treatment With Ruxolitinib Induces High Response Rates in SR-aGVHD - 12 month(s) ago
The phase 3 REACH2 trial showed that early treatment with ruxolitinib 10 mg led to higher response rates vs that seen with the best available therapy in patients with grade II-IV steroid-refractory acute graft-vs-host disease.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Higher response rates were observed with #ruxolitinib given at 10 mg twice a day vs best available therapy for patients aged 12 years and older with grade II-IV SR-aGVHD. #Tandem23 https://t.co/071Nt3arrN
-
-
Mashup Score: 1Retrospective Study Provides Real-World Insight on Ide-cel in R/R Multiple Myeloma With Renal Impairment - 1 year(s) ago
Surbhi Sidana, MD, discusses the real-world safety and efficacy of ide-cel in patients with multiple myeloma and renal impairment, and emphasizes the importance of including this population in future clinical trials examining novel therapies in this disease.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Real-world data from a retrospective study revealed that the CAR T-cell therapy ide-cel is safe and effective in patients with relapsed or refractory multiple myeloma who have renal impairment. @SurbhiSidanaMD @StanfordMed @ASTCT @CIBMTR #mmsm #Tandem23 https://t.co/CqD1EUmu8b https://t.co/5FP03Wq9fK
-
-
Mashup Score: 0Improving outcomes for patients who relapse after alloSCT & evaluating CD19 CARs against EMD in ALL - 1 year(s) ago
Rebecca Epperly, MD, St. Jude Children’s Research Hospital, Memphis, TN, summarizes research presented at the 2023 Transplantation & Cellular Therapy…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rebecca Epperly (@StJudeResearch) summarizes research presented at #Tandem23, commenting on the importance of getting patients who relapse after alloSCT into remission before a secondary transplant & the importance of tumor biology: 👉 https://t.co/nhbBq3URtv 👈 #BMTsm #LeuSM
-
-
Mashup Score: 0
Long-term outcomes did not differ among de novo late acute graft-vs-host disease and classic acute graft-vs-host disease, showing they should be treated the same way.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“Late aGVHD should not be considered a distinct category and patients with late acute GVHD should be treated the same as classic acute #GVHD patients, including eligibility for clinical trials.”-Yu Akahoshi, MD #Tandem23 https://t.co/yizZAIviAr
-
-
Mashup Score: 0Dual-targeted CAR T-cell therapy: Key updates from TCT 2023 - 1 year(s) ago
Here, we summarize three key studies on dual targeted CAR T-cell therapy; a new treatment strategy that may overcome the limitations of currently approved CAR T-cell therapies.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dual targeted CAR T-cell therapy represents an exciting new frontier in the treatment of B-cell malignancies. Check out our summary of key data presented at #Tandem23 👉 https://t.co/hIePxUb8aP. #lymsm
-
-
Mashup Score: 0Phase 3 ZUMA-3 Study of Brexu-cel Elicits Survival Benefit in Relapsed/Refractory B-cell ALL - 1 year(s) ago
Regardless of prior therapies, brexucabtagene autoleucel showed a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, according to subgroup analyses of the phase 3 ZUMA-3 trial.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Brexucabtagene autoleucel showed a survival benefit in patients with relapsed/refractory B-ALL, according to subgroup analyses of the phase 3 ZUMA-3 trial. #Tandem23 | @MoffittNews https://t.co/3zrGuJazdg
-
-
Mashup Score: 02023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR - 1 year(s) ago
Sign In My TimeEST …
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Tandem23 session recordings are now available for purchase. Catch up on what you missed at the meetings with individual session recordings, whole track recordings or all session recordings for a flat rate. View purchase options and instructions: https://t.co/aQ5mQlKXUE https://t.co/01YLkAwEgJ
-
-
Mashup Score: 0Second Tisa-cel Infusion Demonstrates Short MRD-Negative Responses in Pediatric B-ALL - 1 year(s) ago
Tisagenlecleucel reinfusion shows promise as as an effective bridge to hematopoietic stem cell transplantation in pediatric B-cell acute lymphoblastic leukemia.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a retrospective analysis, reinfusion of tisa-cel led to short durations of MRD–negative responses in children and young adults with B-ALL, according findings presented at #Tandem23 https://t.co/iQSlWaydbM
-
-
Mashup Score: 1Real-World Analysis Compares Inpatient and Outpatient CAR T-Cell Therapy in MCL and Follicular Lymphoma - 1 year(s) ago
Inpatient infusion was linked with greater comorbidity burden and increased likelihood of adverse effects in patients with follicular lymphoma who received CAR T-cell therapy, but not in those with mantle cell lymphoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Inpatient infusion was linked with greater comorbidity burden and increased likelihood of AEs in patients with follicular #lymphoma who received CAR T-cell therapy, but not in those with mantle cell lymphoma. #Oncology #Nursing #Tandem23 link: https://t.co/Qyx4rfCIet https://t.co/HDmcpc1qAl
-
For a behind-the-scenes interview about this research with first author @SurbhiSidanaMD at #Tandem23, see our @ASTCT @Emerging_CAR_T interview here ☺️ https://t.co/G6yO8YZbCM